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In Europe, there were an estimated 3.9 million new cases of cancer in 
2018 (Ferlay et al., 2018). In general, survival of most types of cancer 
has increased over the last decade. Five‐year cancer survival rates 
in 2017 in the Netherlands and the United States were 64% and 
67% respectively (Netherlands Cancer Registry, 2019; Siegel, Miller, 
& Jemal, 2019). It is expected that in 2020, there will be roughly 
660,000 patients with cancer in the Netherlands, a fair proportion 
of which being a cancer survivor (Dutch Cancer Society, 2011). 
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Introduction: Symptoms of depression, anxiety and distress are common in the first 
years after a cancer diagnosis, but little is known about the prevalence of these 
symptoms at the long term. The aim of this review was to describe the prevalence of 
symptoms of depression, anxiety and distress in long‐term cancer survivors, five or 
more years after diagnosis, and to provide implications for primary care.
Methods: We performed a systematic literature search in the PubMed, PsycINFO 
and	 CINAHL	 databases.	 Studies	 were	 eligible	 when	 reporting	 on	 the	 prevalence	
of symptoms of depression, anxiety and/or distress in long‐term cancer survivors 
(≥5	years	after	diagnosis),	treated	with	curative	intent.
Results: A	total	of	20	studies	were	included.	The	reported	prevalence	of	depressive	
symptoms (N = 18) varied from 5.4% to 49.0% (pooled prevalence: 21.0%). For anxiety 
(N = 7), the prevalence ranged from 3.4% to 43.0% (pooled prevalence: 21.0%). For 
distress (N = 4), the prevalence ranged from 4.3% to 11.6% (pooled prevalence: 7.0%).
Conclusion: Prevalences of symptoms of depression, anxiety and distress among 
long‐term survivors of cancer do not fundamentally differ from the general popu‐
lation. This is reassuring for primary care physicians, as they frequently act as the 
primary physician for long‐term survivors whose follow‐up schedules in the hospital 
have been completed.
K E Y W O R D S
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Survivors may face various physical and psychosocial sequelae en‐
tailed by their illness or treatment. These sequelae can be severe, 
debilitating and sometimes even permanent. Frequently reported 
symptoms are fatigue, cognitive impairment, sexual dysfunction, 
depression, anxiety and distress (Bloom, 2002; Deimling, Bowman, 
Sterns, Wagner, & Kahana, 2006; Yi & Syrjala, 2017). Yet, psycholog‐
ical problems, such as depression and anxiety, are often under‐diag‐
nosed and under‐treated among patients with cancer, and need early 
identification (Walker, 2014).
Until now, most studies focusing on psychological problems in 
cancer survivors have explored their prevalence mainly within the 
first years after diagnosis, when patients are still in follow‐up at the 
hospital (Stanton, 2006). For example, Krebber et al. (2014) found, in 
their meta‐analysis, a pooled prevalence of depressive disorder among 
cancer patients of 14% during treatment, 9% in the first year post‐
treatment and 8% one year or more post‐treatment (Krebber et al., 
2014).	Moreover,	Watts,	Prescott,	Mason,	McLeod,	and	Lewith	(2015)	
reported in their systematic review pre‐treatment, on‐treatment and 
post‐treatment anxiety prevalence rates in ovarian cancer patients to 
be 19%, 26% and 27% respectively (Watts et al., 2015). Conversely, 
long‐term prevalence of (symptoms of) depression, anxiety and/or dis‐
tress beyond the first 5 years, in cancer survivors with a range of tu‐
mour types, has received limited attention so far. Nevertheless, some 
specific tumour types have been studied already, for example, Maass, 
Roorda,	Berendsen,	Verhaak,	and	Bock	(2015)	reported	a	higher	prev‐
alence of symptoms of depression among long‐term (>2 years) breast 
cancer survivors, compared to the general female population (Maass 
et al., 2015). However, none of the reviews conducted so far focused 
solely on survivors of cancer at least 5 years after diagnosis.
Focusing on the period beyond the first years after diagnosis is 
important, since most cancer follow‐up schedules in hospitals dis‐
continue after 5 years. This 5‐year mark is consistent with the view 
commonly held by the general population, that those who have sur‐
vived for 5 years have a relatively high probability of “being cured” 
(Deimling, 2007). In countries such as the Netherlands, in which the 
general practitioners (GPs) act as gatekeepers in the healthcare sys‐
tem, the GP typically is the primary physician for long‐term cancer 
survivors after the follow‐up period. For these GPs, it is important to 
know how prevalent psychological symptoms are among long‐term 
cancer survivors, in order to be able to provide appropriate or pro‐
active care.
Thus, the aim of this systematic review was to describe the prev‐
alence of symptoms of depression, anxiety and/or distress in long‐
term cancer survivors, five or more years after diagnosis, and to 
provide an overview of implications, related to these psychological 
symptoms in long‐term cancer survivors, for primary care.
2  | METHODS
2.1 | Protocol registration and report
The protocol of this review is available at PROSPERO, the interna‐
tional database of prospectively registered systematic reviews for 
health and social care (registration number CRD42018110822). The 
Preferred	Reporting	 Items	 for	Systematic	Reviews	 (PRISMA	state‐




in	 the	 electronic	 databases	 PubMed	 (MEDLINE),	 PsycINFO	 (Ovid)	
and	CINAHL	(EBSCO),	 from	2000	to	September	30,	2018.	Studies	
were identified using a search syntax based on the PubMed strategy, 
which uses a combination of MeSH terms and free text terms, and 
included synonyms of terms related to cancer, survivor, long term, 
depression, anxiety, distress and prevalence. Where necessary, the 
syntax was adapted for use in the other databases. The PubMed 
search	syntax	can	be	found	in	the	Appendix.
2.3 | Study selection
To assess whether identified studies met the selection criteria, they 
were independently screened on title and abstract by two authors 
(SFAD	and	MJS).	 Full‐text	 articles	were	 retrieved	when	 there	was	
not sufficient information to establish appropriateness for inclusion. 
A	manual	search	of	reference	lists	of	selected	articles	and	relevant	
systematic reviews has been performed to identify further relevant 
studies. Studies were excluded for the following reasons: (a) no 
prevalence	data;	 (b)	 no	 long‐term	 cancer	 survivors	 (≥5	 years	 after	
diagnosis); (c) no data on symptoms of depression, anxiety and/or 
distress;	(d)	no	cancer;	(e)	no	adult	(≥18	years	old)	at	time	of	diagno‐
sis; (f) no treatment with curative intent; and/or (g) other (e.g., full 
text not available, design paper) (Figure 1). In case of disagreement 
during the selection process, a third author (DB) decided upon the 
eligibility of a study.
2.4 | Data extraction and synthesis
A	data	extraction	form	was	developed	to	record	relevant	study	de‐
tails. Data were independently extracted by two authors (OPG and 
MES) and included the following: (a) general study characteristics 
(e.g., author, year of publication, country), (b) study characteristics 
(e.g., recruitment period, design, setting), (c) participant character‐
istics (e.g., age, gender, number, tumour type, time since diagnosis, 
treatment) and (d) symptom characteristics (e.g., measurement, 
prevalence [of symptoms of depression, anxiety and/or distress]). 
We defined symptoms of anxiety, depression and distress as follows: 
these have to be measured using a generic questionnaire or subscale 
of a questionnaire to assess symptoms of depression, anxiety or dis‐
tress. The latter, distress, is typically defined by the presence of an 
adjustment	 disorder	 with	 or	 without	 depression/anxiety.	 All	 data	
were synthesised by describing the prevalence of symptoms of de‐
pression, anxiety and/or distress in adults with cancer assessed at 
least	5	years	after	diagnosis.	Also,	pooled	point	prevalences	and	95%	
confidence	intervals	(CIs)	were	produced	in	STATA	(version	StataSE	
     |  3 of 14BRANDENBARG Et Al.
15) and presented in forest plots. For this, we used the cut‐off val‐
ues	of	>16	for	the	CES‐D,	>8	for	HADS‐A	and	HADS‐D,	and	values	
suggestive of possible depression, anxiety or distress for the other 
questionnaires.
2.5 | Quality assessment
The methodological quality of the included studies was scored in‐
dependently by two authors (DB and CH), by applying the 14 items 
of the NIH's quality assessment tool for Observational Cohort and 
Cross‐Sectional	 Studies	 (National	 Heart,	 Lung,	 &	 Blood	 Institute,	
2014). We slightly adapted the summary score to be applicable 
for our review question. That is, we scored studies as “excellent” if 
they scored “Yes” on the following four questions: (a) Was the study 
population clearly specified and defined?; (b) Was the participation 
rate of eligible persons at least 50%?; (c) Were the exposure meas‐
ures (independent variables) clearly defined, valid, reliable, and im‐
plemented consistently across all study participants?; and (d) Were 
the outcome measures (dependent variables) clearly defined, valid, 
reliable, and implemented consistently across all study participants? 
Exposure was defined as a diagnosis of cancer; outcome was defined 
as symptoms of depression, anxiety or distress. Studies received the 
result “excellent” if they scored positive on all four questions, “good” 
if they scored positive on three out of these four questions, “fair” 
if they scored positive on two questions and “poor” in case of less 
than two positive questions. In case of disagreement, items were dis‐
cussed until consensus was reached, or if necessary, a third author 
(SFAD)	was	consulted.
3  | RESULTS
3.1 | Search results and characteristics of included 
studies
Our original search yielded 644 titles, 392 of which remained after 
the removal of duplicates. Of these titles, 22 met the criteria for a 
full‐text review, of which 20 studies were subsequently included 
(Figure	1).	Agreement	between	researchers	was	95.7%	for	title/ab‐
stract screening, and full consensus was reached after discussion. The 
third author was consulted in four cases during full‐text selection. 
Two studies were based on the same data set, but applied different 
inclusion criteria, resulting in two individual samples (Greenwald & 
McCorkle,	2008;	McCorkle,	Tang,	Greenwald,	Holcombe,	&	Lavery,	
2006).	 A	 total	 of	 14	 studies	 had	 a	 cross‐sectional	 design	 (Boyes,	
Girgis,	Zucca,	&	Lecathelinais,	2009;	Chongpison	et	al.,	2016;	Dahl	
et al., 2005; Goo, Song, Shin, & Ko, 2016; Greenwald & McCorkle, 
2008; Harrison et al., 2011; Henningsohn et al., 2003; Hoffman, 
McCarthy, Recklitis, & Ng, 2009; McCorkle et al., 2006; Pedersen, 
F I G U R E  1   Flow diagram
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Rossen,	 Olesen,	 von	 der	 Maase,	 &	 Vedsted,	 2012;	 Reyes‐Gibby,	
Anderson,	Morrow,	Shete,	&	Hassan,	2012;	Schootman,	Deshpande,	
Pruitt,	Aft,	&	Jeffe,	2010;	Sharpley	et	al.,	2017;	Vogel	et	al.,	2017),	and	
six were prospective cohort studies (Brunault et al., 2013; Chambers 
et	 al.,	 2012;	Chen	 et	 al.,	 2013;	Crespi,	Ganz,	 Petersen,	Castillo,	&	
Caan, 2008; Funk, Karnell, & Christensen, 2012; Johansson et al., 
2011). Most of the included studies were conducted in the United 
States (N = 10) (Chen et al., 2013; Chongpison et al., 2016; Crespi 
et al., 2008; Funk et al., 2012; Greenwald & McCorkle, 2008; 
Hoffman et al., 2009; McCorkle et al., 2006; Reyes‐Gibby et al., 
2012;	Schootman	et	al.,	2010;	Vogel	et	al.,	2017);	other	studies	were	
conducted in Europe (N = 6) (Brunault et al., 2013; Dahl et al., 2005; 
Henningsohn et al., 2003; Johansson et al., 2011; Pedersen et al., 
2012),	Australia/New	Zealand	(N = 3) (Boyes et al., 2009; Chambers 
et	al.,	2012;	Sharpley	et	al.,	2017)	or	Asia	(N = 1) (Goo et al., 2016). 
In total, 17,726 patients (aged 21–93 years) were included across all 
studies. The majority of patients were diagnosed with breast, pros‐
tate or colorectal cancer. Most patients were surgically treated for 
their cancer, and a minority received radiotherapy or chemotherapy. 
The average time since diagnosis across studies, reporting on the 
median or mean number of months since treatment (N = 16), was 
9.6 years (range 5–21 years). Further details on individual study and 
patients’ characteristics have been provided in Table 1.
3.2 | Prevalence of symptoms of depression, 
anxiety and distress
Most studies detailed on the prevalence of depressive symptoms 
(N = 18, with data available for 8,803 patients) (Boyes et al., 2009; 
Brunault et al., 2013; Chambers et al., 2012; Chen et al., 2013; 
Chongpison et al., 2016; Crespi et al., 2008; Dahl et al., 2005; 
Funk et al., 2012; Goo et al., 2016; Greenwald & McCorkle, 2008; 
Harrison et al., 2011; Henningsohn et al., 2003; Johansson et al., 
2011; McCorkle et al., 2006; Pedersen et al., 2012; Reyes‐Gibby 
et	al.,	2012;	Sharpley	et	al.,	2017;	Vogel	et	al.,	2017;	Table	2).	The	
prevalence of anxiety symptoms (N = 7; 4,855 patients) (Boyes et al., 
2009; Chambers et al., 2012; Dahl et al., 2005; Harrison et al., 2011; 
Henningsohn	et	al.,	2003;	Johansson	et	al.,	2011;	Vogel	et	al.,	2017)	
and distress symptoms (N = 4; 9,548 patients; Chambers et al., 2012; 
Dahl et al., 2005; Hoffman et al., 2009; Schootman et al., 2010) was 
reported less frequently (Table 2).
Of the 18 studies detailing on the prevalence of depressive symp‐
toms,	the	depression	subscale	of	the	Hospital	Anxiety	and	Depression	
Scale	 (HADS‐D)	was	 the	most	 frequently	used	 (N = 5). Other mea‐
sures used were the Center for Epidemiological Studies Depression 
questionnaire (CES‐D), the Brief Symptom Inventory (BSI) depres‐
sion	 subscale,	 the	 University	 of	Washington	 Quality	 of	 Life	 ques‐
tionnaire	 (UW‐QOL),	 the	 Short	 Form	Health	 Survey	 (SF),	 the	 Beck	
Depression Inventory (BDI), the Patient Health Questionnaire (PHQ), 
the Symptom Depression Scale (SDS) or a self‐developed question‐
naire. The reported prevalence of depressive symptoms in long‐term 
cancer survivors varied from 5.4% to 49.0%. The pooled prevalence of 
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A	 total	 of	 seven	 studies	 specifically	 reported	 on	 symptoms	 of	
anxiety.	 Most	 of	 these	 studies	 used	 the	 HADS	 anxiety	 subscale	
(HADS‐A)	(N = 4). Other used measures were the BSI anxiety sub‐
scale or a self‐developed questionnaire. The reported prevalence of 
anxiety ranged from 3.4% to 43.0%. The pooled prevalence of pa‐
tients with symptoms of anxiety was estimated to be 21.0%.
In total, four studies reported on distress. Most studies used the 
Kessler Psychological Distress Scale (K6‐scale) to measure symp‐
toms of distress (N	=	2).	Other	measures	used	were	the	HADS	total	
score and the BSI total score. The prevalence of reported distress 
ranged from 4.3% to 11.6%. The mean reported percentage of pa‐
tients with distress symptoms was estimated to be 7.0%.
Further details in regard to symptoms of depression, anxiety and 
distress, and the created forest plots can be found in Table 2 and 
Figure 2 respectively.
3.3 | Quality assessment
The summary scores of the quality assessment were “excellent” for 
half of the included studies (N = 9), nine of the included studies were 
of “good” quality and two studies were scored as having “fair” qual‐
ity. The shortcomings mostly identified were (a) a participation rate 
of <50% (N = 6) and (b) lack of clarity in the description of the study 
population (N = 3). See Figure 3 for more details.
4  | DISCUSSION
4.1 | Main findings
In this systematic review, we reported on the prevalence of symp‐
toms of depression, anxiety and distress in cancer survivors, five or 
more years after diagnosis. The pooled prevalence of symptoms of 
depression and anxiety was 21.0%; the pooled prevalence of dis‐
tress was 7.0%. Most frequently used instruments to measure these 
psychological	symptoms	were	the	HADS	and	the	CES‐D.
4.2 | Interpretation of the findings
Our results suggest that the prevalence of symptoms of depression, 
anxiety and distress among long‐term survivors is comparable with, 
or even slightly below, the prevalence of these symptoms in the gen‐
eral population.
Looking	 more	 specifically	 at	 symptoms	 of	 depression,	 mea‐
sured	 with	 the	 HADS‐D,	 prevalence	 rates	 in	 general	 and	 elderly	
F I G U R E  2   Forest plots of prevalence of symptoms of depression, anxiety and distress
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populations between 10.0% and 23.0% have previously been re‐
ported	 (Djukanovic,	 Carlsson,	 &	 Årestedt,	 2017;	 Hinz	 &	 Brahler,	
2011). In our study, in long‐term cancer survivors, the pooled preva‐
lence of symptoms of depression, measured with this same question‐
naire, was quite low, that is, only 10.0% (8.0%–13.0%). Measurement 
of symptoms of depression in the general population, using the 
CES‐D, showed a prevalence of 21.0% (Smarr & Keefer, 2011), which 
is a bit lower compared to the 27.0% (9.0%–44.0%) in our study. The 
prevalence of symptoms of anxiety in the general population, ac‐
cording	to	the	HADS‐A,	has	been	found	to	be	between	10.0%	and	
21.0%	 (Djukanovic	et	al.,	2017;	Hinz	&	Brahler,	2011).	The	pooled	
prevalence of 20.0% (19.0%–22.0%) found in our study in cancer sur‐
vivors is on the high end of this range.
These relatively low prevalence rates in long‐term cancer sur‐
vivors are in contrast to prevalence rates found among cancer 
patients during and shortly after diagnosis and treatment, when 
higher prevalence rates of psychological symptoms are found 
(Maass et al., 2015; Mitchell, Ferguson, Gill, Paul, & Symonds, 2013; 
Watts et al., 2015). Three aspects might explain this difference: 
(a) former studies did not focus specifically on the period beyond 
the first 5 years after cancer diagnosis, as we did. Earlier research 
showed that adults who have survived cancer for at least 5 years 
frequently identify themselves as cancer survivors and/or as ex‐
patients, rather than as victims or patients (Deimling, Bowman, & 
Wagner, 2007). So, the longer time since diagnosis, and potential 
regained trust in one's health, might positively influence psycholog‐
ical functioning of these survivors; (b) cancer patients who are suf‐
fering from symptoms of depression, anxiety and/or distress might 
be less inclined to participate or continue participation in studies 
regarding psychological sequelae, and herewith be missing in our 
prevalence data. In line with this, an earlier meta‐analysis showed 
that higher levels of depressive symptoms predict higher mortality 
rates (Pinquart & Duberstein, 2010). It is therefore possible that de‐
pressed patients are less frequently long‐term cancer survivors and 
as a result were not included in studies in our review; and (c) cancer 
patients dealing with depressive, anxious and/or distress symp‐
toms, early after their diagnosis, could have received psychological 
treatment, limiting their symptoms on the long term. However, we 
have no data in our study on possible psychological interventions 
or therapies received by the patients, suffering from psychological 
symptoms	≤5	years	after	diagnosis.
Some noteworthy heterogeneity issues in reported prevalence 
rates were observed in this systematic review. That is, in the study of 
Johansson et al. (2011), among survivors of prostate cancer, higher 
prevalence rates of symptoms of depression (49.0%) and anxiety 
(43.0%) were reported. However, a self‐developed questionnaire 
was used, consisting of visual analogue scales for both symptoms of 
depression and anxiety, in which the highest five out of seven cate‐
gories indicated symptoms of depression and anxiety. This relatively 
low cut‐off could explain the high prevalence in this study (Johansson 
et al., 2011). The same applies to the study of Sharpely et al (2017), 
in which a high prevalence of symptoms of depression (39.0%) was 
reported as well (Sharpley et al., 2017). Yet, they used the Zung Self‐
rating	Depression	Scale,	with	a	cut‐off	of	≥40	(range	20–80),	known	
to lead to high numbers of false‐positive classifications (Yesavage et 
al., 1982). On the other hand, in the study of Chambers et al. (2012), 
among survivors of colorectal cancer, a very low (6.0%) prevalence 
of symptoms of depression was reported (Chambers et al., 2012). 
The prevalence rate in this study was measured among survivors in 
a longitudinal study, of whom about 40.0% were enrolled 60 months 
F I G U R E  3   Risk of bias
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after diagnosis. Therefore, the low prevalence could potentially be 
explained by healthy survivor bias.
Studies	using	the	HADS	depression	and	anxiety	scales	showed	
a high agreement in our review. However, there was some variabil‐
ity among studies using the CES‐D. Interestingly, the difference 
among studies using the CES‐D was largest for two specific studies, 
apparently reporting on the same patient population (Greenwald & 
McCorkle, 2008; McCorkle et al., 2006). We were unable to hypoth‐
esise an explanation for the difference in these studies, except that 
there was an age difference in the samples. The slightly older popu‐
lation in the study of McCorkle et al. (2006) reported a lower prev‐
alence though, which is contradictory to most literature suggesting 
an increased prevalence of depressive symptoms with increasing 
age (Djukanovic et al., 2017). In order to enhance comparability and 
interpretation in future research into prevalence rates, we suggest 




presented data on the prevalence of symptoms of depression, anxi‐
ety and distress in cancer survivors, five or more years after their 
cancer diagnosis. This enabled us to provide valuable new insights 
into these symptoms, explicitly in long‐term cancer survivors, most 
of whom are no longer being followed in routine hospital follow‐up. 
Focusing merely on symptoms and excluding clinical diagnoses of 
depression and anxiety disorders is another strength of our study. It 
gives a more accurate estimate of the symptoms’ prevalences, which 
is important since clinically diagnosed patients often have specific 
healthcare needs and treatments. Furthermore, focusing on symp‐
toms only is essential in case of early detection and early interven‐
tion programmes. Finally, our study presented pooled prevalences of 
symptoms of depression, anxiety and distress, using different ques‐
tionnaires, enabling future comparisons.
Nevertheless, we also identified several weaknesses in our 
systematic review. First, since we included studies describing a 
variety of cancer types, we presented data on a heterogeneous 
population of cancer survivors. This hampers description of the 
prevalence for specific patients’ groups. Due to the amount of 
studies found among long‐term survivors, and because a fair pro‐
portion of included studies report on populations with multiple 
cancer types, subgroup analyses for cancer types were not pos‐
sible. Second, most of the studies we included were not designed 
to study the prevalence of symptoms of depression, anxiety and/
or distress. Rather, these were mostly secondary outcomes in 
studies, designed to assess relationships between exposures and 
outcomes among cancer patients. Yet, due to the total number of 
patients included (N = 17,726), we believe our results to hold quite 
some	 value.	 Lastly,	 the	 quality	 assessment	 tool	 used	 in	 the	 cur‐
rent study was not specifically designed for prevalence studies. 
However, the items used to assess overall quality were adapted to 
our review question.
4.4 | Implications for (primary) care and conclusion
Our results suggest that the prevalence rates of symptoms of de‐
pression, anxiety and distress among long‐term cancer survivors 
do not fundamentally differ from the general population. Most 
hospitals have follow‐up schedules for patients after the treat‐
ment for cancer, lasting up to 5 years after treatment. Hereafter, 
in healthcare systems with a gatekeeping function for GPs, these 
physicians function as the primary physician for long‐term can‐
cer survivors. Earlier research showed that patients with cancer 
frequently consult their primary care physician for psychosocial 
issues, starting in the first years after diagnosis (Brandenbarg et 
al., 2017; Roorda, Berendsen, Groenhof, van der Meer, & de Bock, 
2013).	Apart	from	providing	or	referring	to	psychological	care	at	
the short term, GPs might reassure cancer survivors that psycho‐
social sequelae are most prevalent in the first years and likely to 
decline over time. Based on our findings, there seems to be no 
need for primary care physician or other (primary) healthcare pro‐
viders to actively screen all long‐term cancer survivors for symp‐
toms of depression, anxiety and/or distress.
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APPENDIX 1
SE ARCH S TRING
(((((((cancer*[ti]	 OR	 neoplasm*[ti]	 OR	 oncol*[ti])))	 AND	 ((surviv*[ti]	
OR	 long	 term*[ti]	 OR	 long‐term*[ti]	 OR	 longterm*[ti])))	 AND	
(("Depression"[Mesh]	 OR	 "Anxiety"[Mesh]	 OR	 depress*[tiab]	
OR	 dysthym*[tiab]	 OR	 anxiety*[tiab]	 OR	 distress*[tiab]))))	 AND	
("Prevalence"[Mesh] OR prevalen*[tiab])) NOT (((((((((cancer*[ti] OR 
neoplasm*[ti]	 OR	 oncol*[ti])))	 AND	 ((surviv*[ti]	 OR	 long	 term*[ti]	
OR	 long‐term*[ti]	 OR	 longterm*[ti])))	 AND	 (("Depression"[Mesh]	
OR	 "Anxiety"[Mesh]	 OR	 depress*[tiab]	 OR	 dysthym*[tiab]	 OR	
anxiety*[tiab]	 OR	 distress*[tiab]))))	 AND	 ("Prevalence"[Mesh]	
OR	 prevalen*[tiab]))	 AND	 ((infant[MeSH]	 OR	 child[MeSH]	 OR	
adolescent[MeSH]))) NOT ((((((((cancer*[ti] OR neoplasm*[ti] OR 
oncol*[ti])))	 AND	 ((surviv*[ti]	 OR	 long	 term*[ti]	 OR	 long‐term*[ti]	
OR	 longterm*[ti])))	AND	 (("Depression"[Mesh]	OR	 "Anxiety"[Mesh]	
OR depress*[tiab] OR dysthym*[tiab] OR anxiety*[tiab] OR 
distress*[tiab]))))	AND	("Prevalence"[Mesh]	OR	prevalen*[tiab]))	AND	
(adult[MeSH]))) Filters: Publication date from 2000/01/01.
